AR115955A1 - Oligonucleótidos antisentido de acetil-coa carboxilasa2 - Google Patents

Oligonucleótidos antisentido de acetil-coa carboxilasa2

Info

Publication number
AR115955A1
AR115955A1 ARP190102319A ARP190102319A AR115955A1 AR 115955 A1 AR115955 A1 AR 115955A1 AR P190102319 A ARP190102319 A AR P190102319A AR P190102319 A ARP190102319 A AR P190102319A AR 115955 A1 AR115955 A1 AR 115955A1
Authority
AR
Argentina
Prior art keywords
coa
acetyl
human acc2
mrna
nucleic acid
Prior art date
Application number
ARP190102319A
Other languages
English (en)
Original Assignee
Olipass Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olipass Corp filed Critical Olipass Corp
Publication of AR115955A1 publication Critical patent/AR115955A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01002—Acetyl-CoA carboxylase (6.4.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona el derivado de ácido nucleico peptídico que se dirige al sitio de empalme 5’ del pre-ARNm humano ACC2 “exón 12”. Los derivados de ácido nucleico peptídico en la presente inducen fuertemente variantes de empalme del ARNm de ACC2 humano en la célula y son muy útiles para tratar afecciones o trastornos del envejecimiento de la piel asociados con la proteína ACC2 humana.
ARP190102319A 2018-08-14 2019-08-14 Oligonucleótidos antisentido de acetil-coa carboxilasa2 AR115955A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180095124A KR102304280B1 (ko) 2018-08-14 2018-08-14 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드

Publications (1)

Publication Number Publication Date
AR115955A1 true AR115955A1 (es) 2021-03-17

Family

ID=69525636

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102319A AR115955A1 (es) 2018-08-14 2019-08-14 Oligonucleótidos antisentido de acetil-coa carboxilasa2

Country Status (13)

Country Link
US (1) US11739124B2 (es)
EP (1) EP3837274A4 (es)
JP (2) JP2021534146A (es)
KR (1) KR102304280B1 (es)
CN (1) CN112566922A (es)
AR (1) AR115955A1 (es)
AU (1) AU2019320670B2 (es)
BR (1) BR112020026541A2 (es)
CA (1) CA3104658A1 (es)
MX (1) MX2021000998A (es)
SG (1) SG11202012829RA (es)
TW (1) TWI826490B (es)
WO (1) WO2020036353A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304280B1 (ko) 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133444A (en) 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US20030105044A1 (en) 2001-10-17 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of matrix metalloproteinase 1 expression
US20040215006A1 (en) 2003-04-25 2004-10-28 Isis Pharmaceuticals Inc. Modulation of tyrosinase expression
GB0415196D0 (en) * 2004-07-07 2004-08-11 Astrazeneca Ab Polypeptide
US7211423B2 (en) * 2004-07-23 2007-05-01 Bristol-Myers Squibb Co. Acetyl CoA carboxylase 2 sequences and methods
US8299041B2 (en) * 2005-04-08 2012-10-30 Isis Pharmaceuticals, Inc. Compositions and their uses directed to acetyl-CoA carboxylases
BE1017127A6 (nl) 2006-03-24 2008-03-04 Hyfte Luc J R Van Scharnierende bevestiging van een paddelroerwerk.
JP2010075639A (ja) * 2007-10-19 2010-04-08 Shiseido Co Ltd 顔面及び頸部の皮膚状態を改善する美容方法及び装置
KR20090098710A (ko) * 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
US20100166689A1 (en) 2008-12-31 2010-07-01 Revance Therapeutics, Inc. Compositions and Methods for Treating Hyperpigmentation
WO2010123983A1 (en) 2009-04-21 2010-10-28 Yale University Compostions and methods for targeted gene therapy
KR20120073536A (ko) 2010-12-27 2012-07-05 주식회사 파나진 다중전하를 갖는 ｐｎａ
US9499587B2 (en) 2012-01-23 2016-11-22 University Of South Florida Gamma-AApeptides with potent and broad-spectrum antimicrobial activity
US20140314697A1 (en) 2013-04-18 2014-10-23 Corum Inc. Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof
KR101809209B1 (ko) 2016-05-31 2017-12-15 주식회사 올리패스코스메슈티컬즈 두피의 건강 개선을 위한 화장료 조성물 및 이의 제조방법
JP7407592B2 (ja) 2016-08-08 2024-01-04 オリパス コーポレーション アンドロゲン受容体アンチセンスオリゴヌクレオチド
EP3512870B1 (en) 2016-09-16 2022-08-03 Olipass Corporation Scn9a antisense oligonucleotides
JP7089511B2 (ja) 2016-10-11 2022-06-22 オリパス コーポレーション ＨＩＦ１－αアンチセンスオリゴヌクレオチド
AU2017385962B2 (en) * 2016-12-30 2021-09-02 Olipass Corporation Exon skipping by peptide nucleic acid derivatives
JP7503903B2 (ja) 2017-01-06 2024-06-21 オリパス コーポレーション Ｓｎａｐ２５アンチセンスオリゴヌクレオチド
WO2018138585A1 (en) 2017-01-24 2018-08-02 Olipass Corporation Scn9a antisense pain killer
KR102236495B1 (ko) 2017-07-24 2021-04-06 올리패스 주식회사 티로시나아제 안티센스 올리고뉴클레오티드
TWI832851B (zh) 2018-05-18 2024-02-21 韓商奧利通公司 基質金屬蛋白酶-1之反義寡核苷酸
KR102304280B1 (ko) 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
JP2022541896A (ja) 2019-07-18 2022-09-28 オリパス コーポレーション メラノフィリンアンチセンスオリゴヌクレオチド

Also Published As

Publication number Publication date
TWI826490B (zh) 2023-12-21
EP3837274A1 (en) 2021-06-23
AU2019320670A1 (en) 2021-02-11
US11739124B2 (en) 2023-08-29
AU2019320670B2 (en) 2024-04-11
KR20200019509A (ko) 2020-02-24
JP2024038106A (ja) 2024-03-19
SG11202012829RA (en) 2021-02-25
CA3104658A1 (en) 2020-02-20
CN112566922A (zh) 2021-03-26
TW202022115A (zh) 2020-06-16
BR112020026541A2 (pt) 2021-04-06
KR102304280B1 (ko) 2021-09-23
WO2020036353A1 (en) 2020-02-20
MX2021000998A (es) 2021-06-23
US20210363190A1 (en) 2021-11-25
EP3837274A4 (en) 2022-05-18
JP2021534146A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
CY1124292T1 (el) Συνθεσεις για τροποποιηση της εκφρασης tau
NZ747685A (en) Oligonucleotide analogues targeting human lmna
CL2019000149A1 (es) Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociadas a tau. (divisional solicitud 201801652)
CL2017001956A1 (es) Oligomeros antisentido de tau y uso de los mismos
CO2017011484A2 (es) Inhibidores de bromodominio
CO2020010465A2 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CO2020013762A2 (es) Compuestos dirigidos a brm y métodos de uso asociados
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
CR20150490A (es) Derivados de piridina como inhibidores de la quinasa reorganizada durante la transfección (ret)
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
BR112015019440A8 (pt) curativo regulável, kit, uso e método para fortalecimento da pele
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
BR112019002387A2 (pt) oligonucleotídeos antissenso de receptor de andrógeno
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR115955A1 (es) Oligonucleótidos antisentido de acetil-coa carboxilasa2
CY1121427T1 (el) Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς
CO2018012479A2 (es) Compuestos de imidazolona como inhibidores de la elastasa de neutrófilos humana
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων